$1.28
-0.06 (-4.48%)
Open$1.32
Previous Close$1.34
Day High$1.33
Day Low$1.21
52W High$3.23
52W Low$0.95
Volume—
Avg Volume1.89M
Market Cap162.90M
P/E Ratio—
EPS$-1.05
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+349.2% upside
Current
$1.28
$1.28
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.15M | 15.00M | 39.14M |
| Net Income | -126,304,185 | -277,117,909 | -10,010,485 |
| Profit Margin | -2,051.1% | -1,948.5% | -25.6% |
| EBITDA | -124,906,308 | -289,275,944 | -16,322,152 |
| Free Cash Flow | — | — | -10,981,777 |
| Rev Growth | -59.0% | -59.0% | +22.5% |
| Debt/Equity | 0.05 | 0.05 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |